Company: RGNT
Filing Date: 2025-03-11
Form Type: F-1
Source: 0001213900-25-022350
Chunk: 245

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-03-11
Form: F-1
Chunk 245
---
 Issued and outstanding: 246,643 shares; As of June 30, 2024 and December 31, 2023, aggregate liquidation preference of $12,500      |     |      |     |          |  12,500 |   |     |              |  12,500 |   |
| Convertible preferred D-2 shares, NIS 0.01 par value; Authorized:                                                                   
 138,574 shares; Issued and outstanding: 106,982 shares as of June 30, 2024 and December 31, 2023, respectively; As of June 30, 2024 
 and December 31, 2023, aggregate liquidation preference of $3,809                                                                   |     |      |     |          |   3,809 |   |     |              |   3,809 |   |
| Total temporary equity                                                                                                              |     |      |     |          |  35,098 |   |     |              |  35,098 |   |
| Shareholders’ deficit:                                                                                                              |     |      |     |          |         |   |     |              |         |   |
| Ordinary shares, NIS 0.01 par value; Authorized: 1,870,991 shares; issued and outstanding:                                          
 64,879 shares                                                                                                                       |     |      |     |          |      (* | ) |     |              |      (* | ) |
| Additional paid-in capital                                                                                                          |     |      |     |          |   1,042 |   |     |              |   1,042 |   |
| Accumulated deficit                                                                                                                 |     |      |     |          | (39,740 | ) |     |              | (46,947 | ) |
| Total shareholders’ deficit                                                                                                         |     |      |     |          | (38,698 | ) |     |              | (45,905 | ) |
| Total liabilities, temporary equity and shareholders’                                                                               
 deficit                                                                                                                             |     |      |     | $        |     197 |   |     | $            |     360 |   |

| (*) | Represents          
 amount less than $1 |

<div align='center'>The accompanying notes are an integral part of
the unaudited condensed financial statements.

F-2</div>

REGENTIS BIOMATERIALS LTD.

UNAUDITED INTERIM CONDENSED STATEMENTS OF COM